<DOC>
	<DOCNO>NCT02674763</DOCNO>
	<brief_summary>This open label , multicenter Phase 1 study determine MTD , dose schedule RP2D IMGN779 administer mono-therapy adult AML patient CD33 -positive disease .</brief_summary>
	<brief_title>Open-label Study IMGN779 Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</brief_title>
	<detailed_description>In Dose Escalation Phase , patient assign one two schedule . The MTD schedule determine assessment Dose Limiting Toxicities ( DLTs ) . The Dose Expansion Phase consist two cohort base patient response prior therapy accord MTD select .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Dose Escalation : Patients relapse refractory AML Dose Expansion Cohort 1 : Patients relapse AML patient refuse , ar suitable candidate induction therapy Dose Expansion Cohort 2 : Patients refractory AML Dose Escalation : Acute Promyelocytic Leukemia Any concurrent anticancer therapy include chemotherapy , immunotherapy , radiotherapy , biologic investigational agent ( exception hydroxyurea leukapheresis control hyperleukocytosis ) within 14 day five halflives drug , whichever short , prior Cycle 1 Day 1 AML patient know , active leptomeningeal/central nervous system ( CNS ) involvement Prior treatment IMGN779 Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>IMGN779</keyword>
	<keyword>ImmunoGen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>CD33</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Dose Expansion</keyword>
</DOC>